FDA Approves New Drug to Reduce Off Time for Parkinson Disease Medication

Article

A new FDA approval allows istradefylline to be taken as an add-on with other medication to reduce the time medication does not work in Parkinson disease patients.

The US Food and Drug Administration approved istradefylline (Nourianz) tablets as an add-on treatment with levodopa/carbidopa in adult Parkinson disease patients experiencing “off” episodes, a time when medication is not working efficiently, causing symptoms like tremors or walking difficulties to increase.

“Parkinson's disease is a debilitating condition that profoundly impacts patients' lives,” Eric Bastings, MD, acting director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "We are committed to helping make additional treatments for Parkinson's disease available to patients."

The approval was granted to Kyowa Kirin, a Japanese-based pharmaceutical company.

The investigators tested the effectiveness of the new drug in treating “off” episodes in patients with Parkinson disease who are already treated with levodopa/carbidopa during 4, 12-week placebo-controlled clinical trials with a total of 1143 participants.

The patients in all 4 studies treated with Nourianz experienced a statistically significant decrease from baseline in daily “off” time compared to patients receiving a placebo.

Common adverse reactions included involuntary muscle movement, dizziness, constipation, nausea, hallucination, and insomnia.

There are approximately 50,000 Parkinson disease patients in the US diagnosed annually, with about 1 million currently living with the disease.

Related Videos
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
© 2024 MJH Life Sciences

All rights reserved.